정맥주사(IV) 철분 제제 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Intravenous (IV) Iron Drugs Market was valued at approximately USD 1.7 billion in 2023 and is expected to grow at a CAGR of 6.7% from 2024 to 2032. IV iron drugs are specialized formulations of iron administered directly into the bloodstream, commonly used for treating or preventing iron deficiency anemia in patients who cannot effectively absorb oral iron supplements or require rapid iron replenishment.

The market growth is driven by the increasing prevalence of chronic conditions such as chronic kidney disease (CKD), cancer, and inflammatory disorders. These health issues often result in anemia, heightening the need for IV iron therapies to restore iron levels and improve patient outcomes. Additional factors contributing to market expansion include rising awareness of iron deficiency diagnosis, an aging population, and ongoing advancements in IV iron drug formulations.

The overall intravenous (IV) iron drugs industry is segregated based on Drug Type, Application, Distribution Channel, and Region.

The IV iron drugs market is segmented by drug type, including iron dextran, iron sucrose, and ferric carboxymaltose. Among these, the ferric carboxymaltose segment is projected to reach USD 1.5 billion by 2032. This drug offers several benefits, such as high elemental iron concentration, fewer infusions, quicker administration times, and a favorable safety profile, making it a preferred choice for many patients and healthcare providers.

In terms of application, the market is divided into segments like CKD, inflammatory bowel disease, and cancer. The CKD segment accounted for USD 1 billion in 2023 and is expected to remain dominant. CKD patients often struggle with gastrointestinal absorption of iron, making IV iron a more efficient treatment option. Additionally, IV iron helps to increase hemoglobin levels and stimulate red blood cell production, which is crucial for managing anemia in CKD patients.

The distribution channel for IV iron drugs is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment is projected to reach USD 1.4 billion by 2032, benefiting from their expertise in administering IV therapies, monitoring for side effects, and ensuring stringent quality control in drug preparation.

The U.S. market is expected to grow significantly, reaching USD 1 billion by 2032. Factors such as a robust healthcare infrastructure and the rising prevalence of chronic conditions contribute to the increasing demand for IV iron drugs in the country.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Increasing awareness towards timely diagnosis of iron deficiencies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Advancements in intravenous iron drug formulations
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with intravenous iron drugs
    • 3.2.2.2 Adverse reactions and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Iron dextran
• 5.3 Iron sucrose
• 5.4 Ferric carboxymaltose
• 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chronic kidney disease
• 6.3 Inflammatory bowel disease
• 6.4 Cancer
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 AdvaCare Pharma
• 9.3 Akebia Therapeutics, Inc.
• 9.4 AMAG Pharmaceuticals. Inc.
• 9.5 Bayer AG
• 9.6 Covis Pharma GmbH
• 9.7 CSL Limited
• 9.8 Daiichi Sankyo Company, Ltd.
• 9.9 F. Hoffmann-La Roche Ltd.
• 9.10 Fresenius SE and Co. KGaA
• 9.11 Novartis AG
• 9.12 PHARMACOSMOS A/S
• 9.13 Rockwell Medical, Inc.
• 9.14 Sanofi
• 9.15 Zydus Lifesciences Limited